#CRBU hashtag - Bluesky

Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Caribou Biosciences (Nasdaq: CRBU) reported Q4 and full-year 2025 results and clinical updates on March 5, 2026. Key financials: FY2025 licensing revenue $11.2M, GAAP net loss $148.1M ($1.59/sh), non-recurring impairment $21.3M and $142.8M cash at year-end. Management expects cash to fund operations into 2H 2027 while exploring options to fully fund a vispa-cel pivotal trial.Clinical: vispa-cel showed efficacy and durability in 2L LBCL comparable to autologous CAR-T; Caribou is engaging the FDA on pivotal design. CB-011 dose expansion for r/r multiple myeloma initiated with planned data updates in 2026.

1 month ago

#CRBU Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/CRBU/caribou-biosci...

1 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

5 months ago

Most Searched, Monday November 3, 2025 – Crystal Equity Research

Most searched small-cap stocks, Mon Nov 3rd - #LAES #QURE #NVTS #TERN #SLDP #THAR #RXRX #AREC #FUBO #DVLT #CRBU #NVAI #ONDS #RR #PHIO #WRD #PLUG #BBAI #NNVC #CRML - More: crystalequityresearch.com/most-searche... - #smallcap

0 0 0 0

MStrasek

@handle.invalid

5 months ago

#CRBU stock of the day.
$7.93 high of the day,
$6 break of structure - enter short position
$2.50 position closed

3 0 0 0

Stock Master

@stockmaster70.bsky.social

5 months ago

📢 Stocks Trending NOW: #IREN #KVUE #KMB #CIFR #QURE #CRBU #PHIO #IOVA #FUBO #MSPR

0 0 0 0

Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma Caribou Biosciences (Nasdaq: CRBU) reported first clinical data from the CaMMouflage Phase 1 trial of CB-011 in relapsed or refractory multiple myeloma. The 450x10^6 CAR-T cell dose is the recommended dose for expansion (RDE); dose expansion is planned to start by year-end with data expected in 2026. In 12 BCMA-naïve patients at the RDE (median follow-up 8.3 months) the trial showed 92% ORR, 75% ≥CR, and 91% MRD negativity (≤10^-5). Safety was described as manageable but included cytopenias, infections and isolated serious adverse events.

5 months ago

#CRBU Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma

www.stocktitan.net/news/CRBU/caribou-biosci...

0 0 0 0

Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update Caribou Biosciences (NASDAQ: CRBU) reported Q1 2025 financial results and provided updates on its clinical programs. The company ended Q1 with $212.5 million in cash and equivalents, expected to fund operations into H2 2027. Caribou reported a net loss of $40.0 million for Q1 2025.The company recently implemented strategic pipeline prioritization, focusing on its lead oncology programs CB-010 and CB-011, while discontinuing other trials. This resulted in a 32% workforce reduction with estimated cash payments of $2.5-3.5 million.Key upcoming milestones include two clinical datasets in H2 2025: CB-010's ANTLER trial data from a 20-patient cohort in large B cell lymphoma, and CB-011's CaMMouflage trial data from at least 25 multiple myeloma patients at multiple dose levels.

10 months ago

#CRBU Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/CRBU/caribou-biosci...

0 0 0 0

Caribou's Major Restructuring: 32% Staff Cut Powers $212M War Chest for Cancer Breakthroughs Until 2027 Strategic shift focuses on CB-010 and CB-011 cancer programs, cuts 32% workforce, and extends $212.5M cash runway. See full restructuring impact.

11 months ago

#CRBU Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs

www.stocktitan.net/news/CRBU/caribou-biosci...

0 0 0 0

Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Caribou Biosciences (NASDAQ: CRBU) has reported its Q4 and full year 2024 financial results, highlighting significant progress in its clinical pipeline. The company ended 2024 with $249.4 million in cash and equivalents, expected to fund operations into H2 2026.Key financial metrics include:Q4 2024 revenue: $2.1 millionFull year 2024 revenue: $10.0 millionQ4 2024 net loss: $35.5 millionFull year 2024 net loss: $149.1 millionThe company anticipates two major clinical data releases in H1 2025: results from the ANTLER Phase 1 trial of CB-010 in second-line large B cell lymphoma and initial data from the CaMMouflage Phase 1 trial of CB-011 in relapsed/refractory multiple myeloma. The company is advancing four clinical programs across hematologic malignancies and autoimmune diseases.

1 year ago

#CRBU Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/CRBU/caribou-biosci...

0 0 0 0

Important Alert for Caribou Biosciences Shareholders: Contact Gross Law Firm by February 24, 2025 If you are a shareholder of Caribou Biosciences, Inc., it's crucial to reach out to The Gross Law Firm by February 24, 2025, to discuss your rights and potential actions regarding your shares.

1 year ago

Important Alert for Caribou Biosciences Shareholders: Contact Gross Law Firm by February 24, 2025 #USA #New_York #The_Gross_Law_Firm #Caribou_Biosciences #CRBU

0 0 0 0

Levi & Korsinsky Launches Class Action Suit for Caribou Biosciences Investors as Deadline Approaches Levi & Korsinsky, LLP is alerting Caribou Biosciences investors about a class action lawsuit aimed at addressing alleged securities fraud, with a deadline for participation by February 24, 2025.

1 year ago

Levi & Korsinsky Launches Class Action Suit for Caribou Biosciences Investors as Deadline Approaches #USA #New_York #Class_Action #Caribou_Biosciences #CRBU

0 0 0 0

Caribou Biosciences Investors Urged to Join Class Action by The Gross Law Firm The Gross Law Firm alerts Caribou Biosciences investors about a pending class action lawsuit, emphasizing the lead plaintiff deadline of February 24, 2025.

1 year ago

Caribou Biosciences Investors Urged to Join Class Action by The Gross Law Firm #United_States #New_York #Gross_Law_Firm #Caribou_Biosciences #CRBU

0 0 0 0

Important Deadline for Caribou Biosciences Investors Regarding Potential Securities Litigation Rights Investors in Caribou Biosciences, Inc. must reach out to Levi & Korsinsky by February 24, 2025, regarding their rights in a class-action lawsuit.

1 year ago

Important Deadline for Caribou Biosciences Investors Regarding Potential Securities Litigation Rights #United_States #New_York #Levi_&_Korsinsky #Caribou_Biosciences #CRBU

0 0 0 0

Caribou Biosciences Faces Class Action Lawsuit Over Alleged Securities Violations: What Investors Need to Know Caribou Biosciences, Inc. is involved in a class action lawsuit for allegedly misleading investors. Shareholders affected during the class period can seek legal guidance.

1 year ago

Caribou Biosciences Faces Class Action Lawsuit Over Alleged Securities Violations: What Investors Need to Know #United_States #New_York #Class_Action #Caribou_Biosciences #CRBU

0 0 0 0

Pomerantz Law Firm Invites Investors Affected by Caribou Biosciences to Join Class Action Lawsuit Pomerantz Law Firm has announced a class action lawsuit against Caribou Biosciences, urging investors who suffered losses to participate. Act now!

1 year ago

Pomerantz Law Firm Invites Investors Affected by Caribou Biosciences to Join Class Action Lawsuit #United_States #New_York #Pomerantz_Law_Firm #Caribou_Biosciences #CRBU

0 0 0 0

Caribou Biosciences Faces Class Action Lawsuit: Investors Urged to Act Now Caribou Biosciences, Inc. is facing a class action lawsuit alleging securities fraud. Investors are encouraged to take action by the deadline of February 24, 2025.

1 year ago

Caribou Biosciences Faces Class Action Lawsuit: Investors Urged to Act Now #None #New_York #Caribou_Biosciences #CRBU #SEC_Lawsuit

0 0 0 0

Investors Urged to Join Class Action Against Caribou Biosciences for Shareholder Losses Caribou Biosciences shareholders who faced losses are encouraged to join a class action lawsuit for potential recovery. Act before the deadline!

1 year ago

Investors Urged to Join Class Action Against Caribou Biosciences for Shareholder Losses #United_States #New_York #Gross_Law_Firm #Caribou_Biosciences #CRBU

0 0 0 0

Investors Urged to Act Amid Caribou Biosciences Lawsuit for Securities Fraud Caribou Biosciences, Inc. faces a securities fraud lawsuit. Investors are encouraged to contact Levi & Korsinsky to discuss their rights by February 2025.

1 year ago

Investors Urged to Act Amid Caribou Biosciences Lawsuit for Securities Fraud #United_States #New_York #Levi_&_Korsinsky #Caribou_Biosciences #CRBU

0 0 0 0

Class Action Lawsuit Against Caribou Biosciences Seeks Investor Justice by February 2025 Deadline A class action has been filed against Caribou Biosciences, urging investors to join by February 24, 2025. Details about allegations and participation are provided.

1 year ago

Class Action Lawsuit Against Caribou Biosciences Seeks Investor Justice by February 2025 Deadline #USA #New_York #Gross_Law_Firm #Caribou_Biosciences #CRBU

0 0 0 0

Investors in Caribou Biosciences Have Chance to Lead Significant Securities Fraud Lawsuit Caribou Biosciences investors may seek to join a securities fraud class action lawsuit amid serious allegations against the company. The deadline to take action is February 24, 2025.

1 year ago

Investors in Caribou Biosciences Have Chance to Lead Significant Securities Fraud Lawsuit #USA #New_York #Securities_Fraud #Caribou_Biosciences #CRBU

0 0 0 0

Caribou Biosciences Faces Securities Class Action Over Allegations of Fraudulent Statements Caribou Biosciences, Inc. is under legal scrutiny for alleged securities violations. Investors may be entitled to compensation; contact Levi & Korsinsky for guidance.

1 year ago

Caribou Biosciences Faces Securities Class Action Over Allegations of Fraudulent Statements #USA #New_York #Securities_Fraud #Caribou_Biosciences #CRBU

0 0 0 0

Investors of Caribou Biosciences Inc. Urged to Join Class Action Lawsuit Shareholders of Caribou Biosciences Inc. (CRBU) facing losses are encouraged to participate in a class action lawsuit. Contact The Gross Law Firm for more information.

1 year ago

Investors of Caribou Biosciences Inc. Urged to Join Class Action Lawsuit #United_States #New_York #Gross_Law_Firm #Caribou_Biosciences #CRBU

0 0 0 0

Pending Class Action Lawsuit Against Caribou Biosciences: Learn Your Rights Investors in Caribou Biosciences, Inc. should be aware of the pending securities fraud class action. Discover your rights and options before the deadline.

1 year ago

Pending Class Action Lawsuit Against Caribou Biosciences: Learn Your Rights #United_States #New_York #Securities_Fraud #Caribou_Biosciences #CRBU

0 0 0 0

Investors of Caribou Biosciences Have Chance to Lead Class Action for Securities Fraud Investors of Caribou Biosciences, Inc. have a unique opportunity to join a class action lawsuit regarding potential securities fraud. Act before the deadline.

1 year ago

Investors of Caribou Biosciences Have Chance to Lead Class Action for Securities Fraud #USA #New_York #Securities_Fraud #Caribou_Biosciences #CRBU

0 0 0 0

Legal Notification to Caribou Biosciences Shareholders: Class Action Deadline Approaches The Gross Law Firm advises Caribou Biosciences shareholders about a class action lawsuit and an impending deadline for claims, urging prompt action.

1 year ago

Legal Notification to Caribou Biosciences Shareholders: Class Action Deadline Approaches #United_States #New_York #Caribou_Biosciences #CRBU #GLaw_Firm

0 0 0 0

Caribou Biosciences, Inc. Faces Class Action Lawsuit for Securities Fraud Allegations Caribou Biosciences, Inc. is facing a class action lawsuit based on alleged securities law violations, affecting investors from July 2023 to July 2024.

1 year ago

Caribou Biosciences, Inc. Faces Class Action Lawsuit for Securities Fraud Allegations #USA #New_York #Securities_Fraud #Caribou_Biosciences #CRBU

0 0 0 0